TACSTD2 and neoplasm: High TACSTD2 expression was associated with significantly lower histological grade (P < .0001), earlier tumor stage (P < .0001), smaller tumor size (< 20 mm, P < .0001), lower Ki-67 (P < .0001), and longer overall-survival (HR = 0.76; P = .0008), recurrence-free survival (RFS; HR = 0.64; P = .0001) and distant-RFS (HR = 0.64; P = .0011).